Obesity is one of the most serious and urgent public health problems in both developed and developing countries (1). It has reached epidemic proportions in the United States. Since the 1970s, the prevalence of overweight doubled among children of 6 to 11 years of age and tripled among those 12 to 17 years of age (2). Among children aged 6 through 19 years in 2001–2002, 31.5% were at risk for overweight and 16.5% were overweight (more than 3 times the target prevalence of 5%) (3). Furthermore, the problem falls disproportionately on African-American and Hispanic children.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986–1998. JAMA. 2001; 286 (22): 2845–2848
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002; 288 (14): 1723–1727
Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004; 291 (23): 2847–2850
Kaufman FR. Type 2 diabetes in children and youth. Endocrinol Metab Clin North Am. 2005; 34 (3): 659–676
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350 (23): 2362–2374
Dietz WH Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 1998; 101 (3 Pt 2): 518–525. Review
Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults, the Bogalusa Heart Study. N Engl J Med. 1998; 338 (23): 1650–1656
Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 2003; 157 (8): 821–827
Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003; 290 (14): 1884–1890
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P ; Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26 (11): 3160–3167. Review
Goran MI, Bergman RN, Avila Q, Watkins M, Ball GD, Shaibi GQ, Weigensberg MJ, Cruz ML. Impaired glucose tolerance and reduced beta-cell function in overweight Latino children with a positive family history for type 2 diabetes. J Clin Endocrinol Metab. 2004; 89 (1): 207–212
Wiegand S, Maikowski U, Blankenstein O, Biebermann H, Tarnow P, Gruters A. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity–a problem that is no longer restricted to minority groups. Eur J Endocrinol. 2004; 151 (2): 199–206
Keamseng C, Likitmaskul S, Kiattisathavee P, et al. Risk of metabolic disturbance and diabetes development in Thai obese children, 29th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes, Saint-Malo, France, September 3–6, 2003
Lee W, Tang J, Karim H, et al. Abnormalities of glucose tolerance in severely obese Singapore children, 29th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes, Saint-Malo, France, September 3–6, 2003
Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005; 28 (4): 902–909
Goodpaster BH, Wolf D. Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes. Pediatr Diabetes 2004; 5 (4): 219–226. Review
Goodpaster BH, Kelley DE. Skeletal muscle triglyceride: marker or mediator of obesityinduced insulin resistance in type 2 diabetes mellitus? Curr Diab Rep. 2002; 2 (3): 216–222. Review
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004; 350 (7): 664–671
Perseghin G, Scifo P, C obelli F, De Pagliato E, Battezzati A, A rcelloni C, V anzulli A, T estolin G, Pozza G, Del Maschio A, Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 1999; 48 (8): 1600–1606
Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005; 115 (7): 1699–1702. Review
Sinha R, Dufour S, P etersen KF, LeBon V, Enoksson S, Ma YZ, Savoye M, Rothman DL, Shulman GI, Caprio S. Assessment of skeletal muscle triglyceride content by (1)H nuclearA.M.G. Cali, S. Caprio magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 2002; 51 (4): 1022–1027
Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R, Shulman GI, Caprio S . Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003; 362 (9388): 951–957
Shulman GI. Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology (Bethesda). 2004; 19: 183–190. Review
Goodpaster BH, Wolf D. Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes. Pediatr Diabetes 2004; 5 (4): 219–226. Review
Strauss RS. Childhood obesity. Pediatr Clin North Am; 2002; 49 (1): 175–201. Review 26. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16): 1221–1231. Review. No abstract available
Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118 (4): 1388–1393
Inzucchi SE, Petersen KF, Shulman GI. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 347 (10): 768–769; author reply 768–769
Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol. 1997; 146 (7): 565–571
Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr. 2005; 41 (1): 94–98
Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr. 1997; 24 (3): 317–321
Chan DF, Li AM, Chu WC, Chan MH, Wong EM, Liu EK, Chan IH, Yin J, Lam CW, Fok TF, Nelson EA. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord. 2004; 28 (10): 1257–1263
Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003; 143 (4): 500–505
Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, Constable RT, Weiss R, Tamborlane WV, Savoye M, Seyal AA, Caprio S. Alanine Aminotransferase levels and fatty liver in childhood obesity:Associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006; [Epub ahead of print]
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37 (4): 917–923. Erratum in: Hepatology. 2003; 38 (2): 536
Sabir N, Sermez Y, Kazil S, Zencir M. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound. 2001; 14 (2–3): 121–128
Busetto L, Tregnaghi A, Marchi F, De Segato G, Foletto M, Sergi G, Favretti F, Lise M, Enzi G. Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res. 2002; 10 (5): 408–411
Fishbein MH, Mogren C, Gleason T, Stevens WR. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2006; 42 (1): 83–88
Matsuzawa Y, Nakamura T, Shimomura I, Kotani K. Visceral fat accumulation and cardiovascular disease. Obes Res. 1995; 3 Suppl 5: 645S–647S. Review
Caprio S, Hyman LD, Limb C, McCarthy S, Lange R, Sherwin RS, Shulman G, Tamborlane WV. Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol 1995; 269 (1 Pt 1): E118–E126 9 Ectopic Fat Deposition, Adiponectin and Insulin 159
Cruz ML, Bergman RN, Goran MI. Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. Diabetes Care. 2002; 25 (9): 1631–1636
Ford ES. National Health and Nutrition Examination Survey. C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999–2000. Circulation. 2003; 108 (9): 1053–1058. Epub 2003 Aug 18
Trayhurn P, Wood IS. A dipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92: 347–355
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148 (2): 209–214. Review
Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, S taiger H, M aerker E, Haring H, Stumvoll M. P lasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003; 52 (2): 239–243
Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE, Shulman G, C aprio S. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab. 2003; 88 (5): 2014–2018.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7 (8): 941–946
Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci. 1999; 892 146–154
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Cali, A.M.G., Caprio, S. (2008). Ectopic Fat Deposition, Adiponectin and Insulin Resistance in Obese Adolescents. In: Zeitler, P.S., Nadeau, K.J. (eds) Insulin Resistance. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-192-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-59745-192-5_9
Publisher Name: Humana Press
Print ISBN: 978-1-58829-875-1
Online ISBN: 978-1-59745-192-5
eBook Packages: MedicineMedicine (R0)